Quote:
Originally Posted by David Sklansky
Check the details out yourself. But as you know my bottom line is that stock picking is actually the technique of buying and shorting ARGUMENTS rather than companies. And the argument that brought this stock back down to $7.75 after going up to 9.30 and possibly eventually much higher is not going to prevail in my opinion. I'll let others elaborate.
Does anyone like this for a short now? It's down almost half since OP, the "good" trial data was an expensive disaster, and the diet drug field isn't doing very well on the latest data. Since the company has nothing but a patent for a possibly useless drug combination, in a declining field, you'd have to think they're in a bad way with little possible upside.